Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

7 recruiting

Metabolic Dysfunction-Associated Steatohepatitis Trials at a Glance

24 actively recruiting trials for metabolic dysfunction-associated steatohepatitis are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Chandler, Houston, and Chicago. Lead sponsors running metabolic dysfunction-associated steatohepatitis studies include Madrigal Pharmaceuticals, Inc., Beijing Tsinghua Chang Gung Hospital, and Akero Therapeutics, Inc.

Browse metabolic dysfunction-associated steatohepatitis trials by phase

Treatments under study

About Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

Looking for clinical trials for Metabolic Dysfunction-Associated Steatohepatitis? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metabolic Dysfunction-Associated Steatohepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metabolic Dysfunction-Associated Steatohepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.120 enrolled15 locationsNCT07335601
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals132 enrolled3 locationsNCT06836609
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled318 locationsNCT06528314
Recruiting

Rezdiffra Pregnancy and Lactation Registry

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.10 enrolled1 locationNCT07541469
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled291 locationsNCT06419374
Recruiting
Phase 1Phase 2

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

Healthy ParticipantsMASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc99 enrolled1 locationNCT07427680
Recruiting
Phase 2

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rivus Pharmaceuticals, Inc.180 enrolled33 locationsNCT07491458
Recruiting

High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Shanghai East Hospital100 enrolled1 locationNCT07463287
Recruiting

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated SteatohepatitisSleeve Gastrectomy+1 more
Hospices Civils de Lyon20 enrolled2 locationsNCT06868992
Recruiting
Phase 1

ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

Metabolic Dysfunction-Associated Steatohepatitis
Eccogene72 enrolled1 locationNCT07334080
Recruiting

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Centre Hospitalier Universitaire de la Guadeloupe600 enrolled3 locationsNCT07330830
Recruiting

Thermoacoustic Method for Estimating Liver Fat Fraction

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Fatty Liver Disease, Nonalcoholic
Endra Lifesciences49 enrolled1 locationNCT07321925
Recruiting
Phase 2

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis
Boston Pharmaceuticals42 enrolled35 locationsNCT06920043
Recruiting

The Development of MASLD Among Survivors of Breast or Colorectal Cancer

Breast Cancer SurvivorsColorectal (Colon or Rectal) Cancer SurvivorsMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
University of Bern200 enrolled1 locationNCT07280143
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+14 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting
Phase 4

Resmiterom Efficacy & Safety in Patients With MASH

MASH - Metabolic Dysfunction-Associated Steatohepatitis
Nabiqasim Industries (Pvt) Ltd165 enrolled1 locationNCT07249788
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASH - Metabolic Dysfunction-Associated SteatohepatitisNAFLDNASH
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Not Applicable

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisNAFLD+4 more
E-Scopics120 enrolled3 locationsNCT06661655
Recruiting
Not Applicable

To Test Whether Time-restricted Eating Coupled With a Healthy Diet is Beneficial in Liver Cancer Patients

Obesity and OverweightLiver Cancer, AdultMASH - Metabolic Dysfunction-Associated Steatohepatitis
University of California, San Diego50 enrolled1 locationNCT06824974
Recruiting
Not Applicable

Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)

MASH - Metabolic Dysfunction-Associated SteatohepatitisSteatosis of LiverMASH With Fibrosis
Queen Mary University of London72 enrolled2 locationsNCT07013916